NASDAQ:IRIX

IRIDEX Stock Forecast, Price & News

$7.10
-0.10 (-1.39 %)
(As of 09/16/2021 02:54 PM ET)
Add
Compare
Today's Range
$7.06
$7.21
50-Day Range
$6.29
$7.98
52-Week Range
$1.60
$9.71
Volume1,900 shs
Average Volume190,818 shs
Market Capitalization$112.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
30 days | 90 days | 365 days | Advanced Chart
Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.


IRIDEX logo

About IRIDEX

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.70 out of 5 stars

Computer And Technology Sector

568th out of 857 stocks

Electromedical Equipment Industry

18th out of 31 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

Is IRIDEX a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRIDEX stock.
View analyst ratings for IRIDEX
or view top-rated stocks.

What stocks does MarketBeat like better than IRIDEX?

Wall Street analysts have given IRIDEX a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IRIDEX wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for IRIDEX
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) posted its quarterly earnings results on Tuesday, May, 11th. The medical equipment provider reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.14). The medical equipment provider earned $11.96 million during the quarter, compared to the consensus estimate of $9.90 million. IRIDEX had a negative net margin of 5.41% and a negative trailing twelve-month return on equity of 25.31%.
View IRIDEX's earnings history
.

How has IRIDEX's stock been impacted by Coronavirus?

IRIDEX's stock was trading at $1.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IRIX stock has increased by 260.4% and is now trading at $7.10.
View which stocks have been most impacted by COVID-19
.

What guidance has IRIDEX issued on next quarter's earnings?

IRIDEX updated its FY 2021 earnings guidance on Thursday, September, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50 million-$52 million, compared to the consensus revenue estimate of $50.53 million.

What price target have analysts set for IRIX?

1 Wall Street analysts have issued twelve-month target prices for IRIDEX's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate IRIDEX's stock price to reach $11.00 in the next year. This suggests a possible upside of 54.9% from the stock's current price.
View analysts' price targets for IRIDEX
or view top-rated stocks among Wall Street analysts.

Who are IRIDEX's key executives?

IRIDEX's management team includes the following people:
  • David I. Bruce, President, Chief Executive Officer & Director
  • Patrick Mercer, Chief Operating Officer
  • Fuad Ahmad, Chief Financial Officer
  • George R. Marcellino, Vice President-Clinical Affairs
  • Susan Bruce, Executive Administrator

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX CEO Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among IRIDEX's employees.

Who are some of IRIDEX's key competitors?

What other stocks do shareholders of IRIDEX own?

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.17%), Vanguard Group Inc. (3.24%), Bridgeway Capital Management LLC (1.68%), Essex Investment Management Co. LLC (1.30%), Isthmus Partners LLC (1.18%) and Dimensional Fund Advisors LP (1.16%). Company insiders that own IRIDEX stock include Robert Earle Grove and Scott Shuda.
View institutional ownership trends for IRIDEX
.

Which major investors are selling IRIDEX stock?

IRIX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EAM Investors LLC, Neuberger Berman Group LLC, Isthmus Partners LLC, and Invenomic Capital Management LP.
View insider buying and selling activity for IRIDEX
or view top insider-selling stocks.

Which major investors are buying IRIDEX stock?

IRIX stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Millennium Management LLC, Bridgeway Capital Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., State Street Corp, Renaissance Technologies LLC, and PDT Partners LLC. Company insiders that have bought IRIDEX stock in the last two years include Robert Earle Grove, and Scott Shuda.
View insider buying and selling activity for IRIDEX
or or view top insider-buying stocks.

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $7.10.

How much money does IRIDEX make?

IRIDEX has a market capitalization of $112.41 million and generates $36.35 million in revenue each year. The medical equipment provider earns $-6,330,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does IRIDEX have?

IRIDEX employs 89 workers across the globe.

What is IRIDEX's official website?

The official website for IRIDEX is www.iridex.com.

Where are IRIDEX's headquarters?

IRIDEX is headquartered at 1212 Terra Bella Avenue, Mountain View CA, 94043.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at (650) 940-4700 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.